Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting.
Single-arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B-cell lymphomas but with significant toxicities and at exceptionally high costs. These results support the benefit of CAR T-cell treatment for patients with R/R aggressive B-cell lymphoma in routine clinical care.
Single-arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B-cell lymphomas but with significant toxicities and at exceptionally high costs. These results support the benefit of CAR T-cell treatment for patients with R/R aggressive B-cell lymphoma in routine clinical care.
What the study was
- Study design
- Cohort study
- Sample size
- 314
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- British journal of haematology
Why it surfaced
Relevant Hematologic malignancies study (novel treatment potential) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.